Baidu
map

Eur Urol:不同初始治疗方案对局限性前列腺癌患者的长期心理和生活质量影响。

2017-08-28 fengxiangxin MedSci原创

长期的心理健康和生活质量是低风险前列腺癌患者在决定是否接受积极治疗时重要的考虑因素。

长期的心理健康和生活质量是低风险前列腺癌患者在决定是否接受积极治疗时重要的考虑因素。

该研究的主要目的是评估主动监测(AS)和/或观察等待(WW)对低风险局限性前列腺癌患者的心理和生活质量的长期影响。结果验证涉及前列腺癌患者与健康相关的6个生活质量领域和9个精神领域。使用线性回归对前列腺癌不同处理组结果得分调整后的平均差异(AMDS)进行评估。

前列腺癌的护理和结果研究是一项在新南威尔士和澳大利亚进行的以人群为基础的前瞻性队列研究。参与者是在70岁以前诊断为低风险局限性前列腺癌的患者,并对他们进行10年的随访。

在确诊后的9–11年,以AS/ WW作为最初治疗方案的患者:(1)相比以放疗/高剂量率近距离放射治疗作为最初治疗方案的患者出现更高水平的苦恼和过度反应(分别有AMD= 5.9;95%置信区间C[ 0.5,11.3 ]和AMD= 5.4;95% 置信区间 [ 0.2,10.5 ])。

(2)相比以低剂量率近距离放射治疗作为最初治疗方案的患者出现更高水平的苦恼和逃避行为(分别有AMD=5.3;95% 置信区间[ 0.2,10.3 ]和AMD= 7;95% 置信区间 [ 0.5,13.5 ])。

(3)与以根治性前列腺切除术作为最初治疗方案的患者相比,有更好的尿失禁评分(AMD=–9.1;95% 置信区间 [–16.3,–2 ])。

(4)与以放疗/高剂量率近距离放射治疗作为最初治疗方案的患者相比,有更少的肠应激(AMD=–16.8;95%置信区间 [–27.6,–6 ])。此外,没有发现其他显著差异。

尽管在AS/ WW和各种积极治疗方案之间存在诸如苦恼、过度反应、逃避、尿失禁和应激等长期差异, 但是大多数结果比较在这些群体之间是相似的。

原始出处:


本文系梅斯医学(MEDSCI)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1905012, encodeId=3a1619050121e, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Tue May 15 17:03:00 CST 2018, time=2018-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022106, encodeId=5cc320221061f, content=<a href='/topic/show?id=0ca732196ef' target=_blank style='color:#2F92EE;'>#初始治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32196, encryptionId=0ca732196ef, topicName=初始治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7482500171, createdName=ms4468361851264128, createdTime=Thu Apr 19 01:03:00 CST 2018, time=2018-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924025, encodeId=fcf019240258e, content=<a href='/topic/show?id=61d24e655df' target=_blank style='color:#2F92EE;'>#局限性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47655, encryptionId=61d24e655df, topicName=局限性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Sat Sep 09 01:03:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460466, encodeId=06ed1460466fd, content=<a href='/topic/show?id=ebf74e65779' target=_blank style='color:#2F92EE;'>#局限性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47657, encryptionId=ebf74e65779, topicName=局限性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8256335432, createdName=yang0212, createdTime=Wed Aug 30 10:03:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238071, encodeId=c8032380e1e6, content=是什么决定了患者的初始选择?, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRr63iayTjay9otQ2yDAmbravgszHBxSLHIJpTZ8uNAiaa87bfqeDpEPTUicdBhBlf5yABuAj1OwClO4/0, createdBy=c3622063904, createdName=fengxiangxin301, createdTime=Mon Aug 28 19:29:19 CST 2017, time=2017-08-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1905012, encodeId=3a1619050121e, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Tue May 15 17:03:00 CST 2018, time=2018-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022106, encodeId=5cc320221061f, content=<a href='/topic/show?id=0ca732196ef' target=_blank style='color:#2F92EE;'>#初始治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32196, encryptionId=0ca732196ef, topicName=初始治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7482500171, createdName=ms4468361851264128, createdTime=Thu Apr 19 01:03:00 CST 2018, time=2018-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924025, encodeId=fcf019240258e, content=<a href='/topic/show?id=61d24e655df' target=_blank style='color:#2F92EE;'>#局限性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47655, encryptionId=61d24e655df, topicName=局限性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Sat Sep 09 01:03:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460466, encodeId=06ed1460466fd, content=<a href='/topic/show?id=ebf74e65779' target=_blank style='color:#2F92EE;'>#局限性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47657, encryptionId=ebf74e65779, topicName=局限性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8256335432, createdName=yang0212, createdTime=Wed Aug 30 10:03:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238071, encodeId=c8032380e1e6, content=是什么决定了患者的初始选择?, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRr63iayTjay9otQ2yDAmbravgszHBxSLHIJpTZ8uNAiaa87bfqeDpEPTUicdBhBlf5yABuAj1OwClO4/0, createdBy=c3622063904, createdName=fengxiangxin301, createdTime=Mon Aug 28 19:29:19 CST 2017, time=2017-08-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1905012, encodeId=3a1619050121e, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Tue May 15 17:03:00 CST 2018, time=2018-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022106, encodeId=5cc320221061f, content=<a href='/topic/show?id=0ca732196ef' target=_blank style='color:#2F92EE;'>#初始治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32196, encryptionId=0ca732196ef, topicName=初始治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7482500171, createdName=ms4468361851264128, createdTime=Thu Apr 19 01:03:00 CST 2018, time=2018-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924025, encodeId=fcf019240258e, content=<a href='/topic/show?id=61d24e655df' target=_blank style='color:#2F92EE;'>#局限性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47655, encryptionId=61d24e655df, topicName=局限性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Sat Sep 09 01:03:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460466, encodeId=06ed1460466fd, content=<a href='/topic/show?id=ebf74e65779' target=_blank style='color:#2F92EE;'>#局限性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47657, encryptionId=ebf74e65779, topicName=局限性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8256335432, createdName=yang0212, createdTime=Wed Aug 30 10:03:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238071, encodeId=c8032380e1e6, content=是什么决定了患者的初始选择?, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRr63iayTjay9otQ2yDAmbravgszHBxSLHIJpTZ8uNAiaa87bfqeDpEPTUicdBhBlf5yABuAj1OwClO4/0, createdBy=c3622063904, createdName=fengxiangxin301, createdTime=Mon Aug 28 19:29:19 CST 2017, time=2017-08-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1905012, encodeId=3a1619050121e, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Tue May 15 17:03:00 CST 2018, time=2018-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022106, encodeId=5cc320221061f, content=<a href='/topic/show?id=0ca732196ef' target=_blank style='color:#2F92EE;'>#初始治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32196, encryptionId=0ca732196ef, topicName=初始治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7482500171, createdName=ms4468361851264128, createdTime=Thu Apr 19 01:03:00 CST 2018, time=2018-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924025, encodeId=fcf019240258e, content=<a href='/topic/show?id=61d24e655df' target=_blank style='color:#2F92EE;'>#局限性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47655, encryptionId=61d24e655df, topicName=局限性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Sat Sep 09 01:03:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460466, encodeId=06ed1460466fd, content=<a href='/topic/show?id=ebf74e65779' target=_blank style='color:#2F92EE;'>#局限性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47657, encryptionId=ebf74e65779, topicName=局限性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8256335432, createdName=yang0212, createdTime=Wed Aug 30 10:03:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238071, encodeId=c8032380e1e6, content=是什么决定了患者的初始选择?, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRr63iayTjay9otQ2yDAmbravgszHBxSLHIJpTZ8uNAiaa87bfqeDpEPTUicdBhBlf5yABuAj1OwClO4/0, createdBy=c3622063904, createdName=fengxiangxin301, createdTime=Mon Aug 28 19:29:19 CST 2017, time=2017-08-28, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1905012, encodeId=3a1619050121e, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Tue May 15 17:03:00 CST 2018, time=2018-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022106, encodeId=5cc320221061f, content=<a href='/topic/show?id=0ca732196ef' target=_blank style='color:#2F92EE;'>#初始治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32196, encryptionId=0ca732196ef, topicName=初始治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7482500171, createdName=ms4468361851264128, createdTime=Thu Apr 19 01:03:00 CST 2018, time=2018-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924025, encodeId=fcf019240258e, content=<a href='/topic/show?id=61d24e655df' target=_blank style='color:#2F92EE;'>#局限性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47655, encryptionId=61d24e655df, topicName=局限性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Sat Sep 09 01:03:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460466, encodeId=06ed1460466fd, content=<a href='/topic/show?id=ebf74e65779' target=_blank style='color:#2F92EE;'>#局限性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47657, encryptionId=ebf74e65779, topicName=局限性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8256335432, createdName=yang0212, createdTime=Wed Aug 30 10:03:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238071, encodeId=c8032380e1e6, content=是什么决定了患者的初始选择?, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRr63iayTjay9otQ2yDAmbravgszHBxSLHIJpTZ8uNAiaa87bfqeDpEPTUicdBhBlf5yABuAj1OwClO4/0, createdBy=c3622063904, createdName=fengxiangxin301, createdTime=Mon Aug 28 19:29:19 CST 2017, time=2017-08-28, status=1, ipAttribution=)]
    2017-08-28 fengxiangxin301

    是什么决定了患者的初始选择?

    0

相关资讯

Eur Urol:放疗后怀疑前列腺癌复发,穿刺部位如何选?

对初次放疗没有反应的前列腺癌男性患者来说,精确了解肿瘤复发或持续的部位有利于认识治疗失败的原因。

盘点:近期前列腺癌研究进展一览

前列腺癌是指发生在前列腺的上皮性恶性肿瘤。2004年WHO《泌尿系统及男性生殖器官肿瘤病理学和遗传学》中前列腺癌病理类型上包括腺癌(腺泡腺癌)、导管腺癌、尿路上皮癌、鳞状细胞癌、腺鳞癌。其中前列腺腺癌占95%以上,因此,通常我们所说的前列腺癌就是指前列腺腺癌。梅斯医学小编整理了近期前列腺癌的研究进展,与大家一起分享学习!【1】Nat Genet:原发性前列腺癌中,TMPRSS2-ERG调控转录

Eur Urol:向精密泌尿系肿瘤学方向迈进,一种新型的AR拮抗剂

Darolutamide(ODM-201)是一种新型的雄激素受体(AR)拮抗剂,其化学结构与目前批准的AR拮抗剂有明显差异,主要针对野生型和突变型的配体结合域突变体抑制AR核转位。

JCO:雄激素剥夺治疗(ADT)对于前列腺癌老年患者来说,没有增加AD风险,对痴呆症也没有任何有意义的风险!

近日,在医学权威杂志JAMA上面发表了一篇研究文章,研究人员在调整其他癌症治疗后,探讨雄激素剥夺治疗(ADT)对于前列腺癌患者来说患阿尔兹海默症的相对风险。

Cancer Immunol Immunother:DNA编码的抗前列腺特异膜抗原单克隆抗体的新的前列腺癌免疫疗法

前列腺特异膜抗原(PSMA)在恶性肿瘤前列腺细胞中高水平表达,并且很可能是前列腺恶性肿瘤治疗的一个重要的药物靶标。目前已PSMA为治疗靶标的免疫疗法包括肽、细胞、载体或者基于DNA的疫苗以及PSMA特异性单克隆抗体(mAb)被动治疗。传统的mAb免疫治疗具有很多的逻辑和实践限制,包括高额的生产费用和由于短的mAb血清半衰期而导致的频繁剂量输入。最近,有研究人员阐释了一个基于抗体的免疫疗法的新的治疗

Brit J Cancer:SGK1抑制剂通过mTOR-Foxo3a信号通路诱导自我吞噬依赖的细胞凋亡

尽管之前的研究表明SGK1抑制剂具有推迟癌症进展的作用,但是潜在的机制还没有被阐释。最近,有研究人员在人类前列腺癌(PCa)细胞系和PC3异种种植中调查了对GSK650394处理和SGK1沉默(或者超表达)后的细胞学响应。使用的技术包括流式细胞术、蛋白免疫印迹、免疫荧光和透射电子显微镜以及免疫组化技术。研究结果发现,SGK1抑制剂可以通过GSK650394或者SGK1 shRNA调节,来诱导G2/

Baidu
map
Baidu
map
Baidu
map